Elevated Fasting Glucagon in Adolescents with Combined IFG+IGT- Alpha-Cell Hyperactivity Independent of Beta-Cell Function
Journal of the Endocrine Society · 2026-11-10
DOI: 10.1210/jendso/bvag262 ↗Abstract
Abstract Introduction The exact role of glucagon in pediatric prediabetes and its progression to type-2-diabetes mellitus (T2D) remains unclear. Elevated fasting glucagon levels are believed to contribute to the transition from normoglycemia to overt diabetes. This study aimed to determine if higher fasting glucagon concentrations characterize distinct prediabetic subgroups within a cohort of adolescents with obesity or overweight. Methods Adolescents with obesity or overweight (n=208), median age 13.6 years (Q1:11.7;Q3:15.5 years), from the Beta-JUDO study were grouped according to their glycemic state following an Oral Glucose Tolerance Test as normal fasting glucose and normal glucose tolerance (NGM), impaired glucose tolerance (IGT), impaired fasting glucose (IFG), a combination of the previous two (IFG+IGT). Groups were analyzed for fasting glucagon, fasting insulin and indices of beta-cell function and insulin-sensitivity. Results for each prediabetic subgroup were compared to that in normoglycemic adolescents with obesity or overweight. Results Fasting glucagon was significantly increased in individuals with IFG+IGT (p<0.05). Median fasting glucagon levels were 44.2 ng/L (Q1:38.0;Q3:50.3 ng/L) compared to 35.4 ng/L (Q1:26.3;Q3:48.8 ng/L) in NGM; 39.1 ng/L (Q1:34.8;Q3:60.6 ng/L) in IGT and 37.6 ng/L (Q1:25.6;Q3:47.0 ng/L) in IFG. Hyperglucagonemia in IFG+IGT remained significant after Propensity Score Matching for oral Disposition Index (oDI), indicating similar beta-cell function and insulin-resistance (p<0.05). Conclusion These findings demonstrate a distinct alpha-cell dysfunction in adolescents with IFG+IGT, reflected by significantly elevated fasting glucagon, independent of beta-cell function, despite prevailing hyperglycemia.
EUVIMED